impressive promotion , page-77

Hello Onshow,

My 2 cents....

I believe it is valid to consider this a med/biotech for financial / modelling purposes given it's main, upcoming product must navigate the same risky, regulatory hoops and undertake clinical studies as any other related product on the market.

What's interesting about Isonea's offering is that on top of the traditional, business through physician (with the wheezeometer) piece, it also has a direct B2C product with app development. The latter, cheap to develop (comparatively) and the ability to provide cashflow (hopefully) to minimise pain on shareholders.

We all write conjecture, and the essence of mine is this: if ISN can maintain schedule and survive another couple of years, it *should* be cashflow neutral. And when it's there, it'll either have a PE ratio of 1 or the share price will rise. I'm happy either way.